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AbstrACt
background We sought to understand the beliefs, 
social norms and logistical factors that affect human 
papillomavirus (HPV)-positive women’s uptake of 
cryotherapy treatment as part of a two-part cervical 
cancer screening strategy in rural Kenya.
Methods In-depth interviews within a parent cluster-
randomised trial.
setting Government-run county hospital in western 
Kenya.
Participants 273 of 372 (73.4%) HPV-positive women 
who underwent cryotherapy
results Many women feared that an HPV infection meant 
they would develop cancer. Almost all women reported 
initial fear of the treatment procedure, followed by a more 
positive experience than anticipated. Lacking funds for 
transportation to the treatment site was the most common 
barrier. Women felt that decentralised treatment would be 
the most important facilitator of greater access. Spousal 
encouragement and financial support were key facilitators 
of treatment access, however many women felt that other 
husbands in the community would not be supportive. 
Women described successfully acquiring treatment as 
empowering, and almost all would recommend seeking 
cryotherapy to other women who test HPV-positive. Most 
felt eager to share their own experiences with others to 
encourage treatment.
Conclusions The main facilitators of treatment access 
were understanding of the health risks and sense of 
empowerment. A decentralised treatment model or 
transportation support may facilitate access, along with 
improved health messaging about HPV infection, cancer 
and the treatment process. Focusing on women’s personal 
feelings of empowerment may further improve uptake and 
satisfaction. These data will be used to design a strategy 
to improve linkage to treatment.
trial registration NCT02124252.
IntroduCtIon
Cervical cancer, despite being one of the most 
preventable cancers through vaccination and 
screening, remains the fourth most common 
cancer among women worldwide.1 Now rare 
in wealthier countries due to the success of 
the cytology-based prevention programme, 
cervical cancer continues to be a major public 
health issue in low-income and middle-in-
come countries (LMICs). Effective popula-
tion-based screening, coupled with linkage 
to treatment for screen-positive women, is 
critical to preventing the development of 
cervical cancer. In Kenya, where screening 
rates range between 3% and 14%, and vacci-
nation for human papillomavirus (HPV) is 
not yet available, cervical cancer is the second 
most common cancer in women, and the 
leading cause of cancer-related mortality.2
Strategies to address the lack of a screening 
programme in LMICs include simpler 
screening techniques coupled with cryo-
therapy for women who screen positive. 
Cryotherapy is relatively inexpensive, can 
be performed by non-physician providers 
and does not require electricity. It has been 
promoted along with visual inspection with 
acetic acid (VIA) as part of a same day ‘see 
& treat’ strategy, although the expense and 
strengths and limitations of the study
 ► This study provides insight into women’s experience 
obtaining cryotherapy after a receiving positive hu-
man papillomavirus test result in western Kenya.
 ► The perspectives provided will allow for improved 
contextualisation of cervical cancer prevention pro-
grammes in similar settings.
 ► These qualitative findings are exploratory, and may 
not be reflective of larger patterns or associations.
 ► Women were interviewed by trained study staff, so 
there may have been social desirability bias.
 ► We did not interview women who were lost to fol-
low-up, and may therefore have had even more bar-
riers than those identified in this study.
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logistical challenges of maintaining supplies, space and 
personnel for cryotherapy in remote settings make single-
visit strategies impossible in most settings.3 4
Another simple screening technique is low-cost HPV 
testing.5 6 The WHO incorporated the growing body of 
evidence supporting HPV testing into recommendations 
for a screening programme in low resource settings.7 
The current guidelines include HPV primary screening 
as the preferred modality, followed by cryotherapy. As 
HPV testing has become more widely available and the 
evidence for its use more convincing, the programme is 
starting to move from ‘see & treat’ to ‘screen & treat,’ 
referring women for treatment based on a positive HPV 
result. While this may be more effective at decreasing 
cervical precancer and cancer, there are no currently 
available HPV tests that allow for same-visit results. There-
fore, the programme must take into consideration how 
to deliver HPV test results and counselling in a way that 
fosters understanding and facilitates women’s uptake 
of the appropriate follow-up. An effective HPV-based 
screening programme must take into account the multi-
tude of sociocultural factors such as stigma, fear and 
misperceptions, along with the logistical and health 
systems factors that affect a woman’s decision-making 
and ability to seek screening, understand her results and 
obtain treatment if needed.
While multiple studies have evaluated effective 
screening methods for women in western Kenya, there 
remains a gap in understanding effective strategies to 
link women who screen positive for HPV to appropriate 
follow-up and treatment.8–12 Given that HPV-based strate-
gies are relatively new to LMICs, there are very little quali-
tative data exploring women’s experience with treatment. 
Understanding the knowledge, beliefs, social norms and 
logistical factors that affect women’s decision and ability 
to seek treatment is essential in the design of effective 
context-specific treatment strategies. We used the Consol-
idated Framework for Implementation Research (CFIR) 
to explore the contextual factors that may have facilitated 
HPV-positive women’s access to appropriate treatment 
within a community-based screening programme.13
MAterIAls And Methods
study design
We used qualitative data to explore the barriers and facili-
tators of treatment access for women who tested HPV-pos-
itive as part of a two-phase cluster-randomised trial in 
rural western Kenya.14 In the first phase, 12 communities 
in Migori County were randomised to screening using 
self-collected HPV tests either through community health 
campaigns in central locations in the villages (CHCs) or 
in health facilities. In both the CHC and health facility 
arms, education and outreach was led by community 
health volunteers, and women who tested HPV-positive 
were notified of their results and referred to the Migori 
County Hospital for treatment with cryotherapy.15 After 
treatment, women were invited to participant in an 
in-depth interview (IDI) regarding their experience.
The distance between Migori County Hospital and 
the 12 study communities ranged from 11 km to 94 km. 
Transport around the county was available via motor-
cycles, public buses and private taxis. In the hospital 
compound, treatment was provided by nurses who had 
undergone additional training in both cryotherapy and 
study procedures prior to study initiation. The medical 
superintendent and an experienced nurse facilitator 
provided supervision as needed. Women underwent VIA 
prior to treatment, followed by cryotherapy, unless the 
cervical anatomy was abnormal, the lesion was too large 
for the probe or there was suspicion for cancer. In the first 
two cases, the woman would be referred for a loop elec-
trosurgical excision procedure (LEEP) within the same 
hospital. If there was suspicion for cancer, she was offered 
a biopsy and referred for management of cancer. All costs 
associated with cryotherapy or LEEP were covered by the 
study. Women did not receive compensation for transport 
or monetary incentives for participation in the study.
data sources
IDI guides were developed using selected CFIR constructs 
to elicit responses about the client-sided experience and 
perceptions of treatment (table 1). Selected constructs 
included adaptability, patient needs and resources and 
complexity of proposed intervention methods.
IDI guides were developed in English and translated 
and conducted in the most common local languages 
(Dholuo and Kiswahili) by researchers fluent in those 
languages. The first part of the IDIs consisted of closed-
ended questions about sociodemographic characteris-
tics, sexual behaviour, gynaecological history, HIV status, 
cervical cancer screening and HPV. Interviewers entered 
these data directly into Open Data Kit installed onto study 
tablets. The second part of the interviews consisted of 
open-ended questions that probed women on what they 
understood about HPV and treatment for HPV, their feel-
ings and experience with treatment, barriers and facilita-
tors to treatment, stigma and desire for privacy, and male 
and community leader roles in facilitating cervical cancer 
prevention. Interviews lasted between 15 min and 25 min. 
These data were recorded on the tablets, and then tran-
scribed and translated. All translations were reviewed with 
the audio by the study coordinator for accuracy.
data analysis
Using thematic analysis, one member of the research 
team created the codebook using both the IDI guide for 
structure and four sample interviews to identify additional 
themes that together facilitated a more nuanced interpre-
tation of the data .16 The codebook was then reviewed 
and revised by the entire team, followed by a round in 
which all four researchers sample coded 10 interviews 
to test and revise the codebook. All analysis and code-
book development was done using NVivo V.11 software 
(QSR International, London, UK). The team then met 
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Table 1 Refined CFIR constructs and key findings regarding HPV-positive women’s experiences with a referral-based 
cryotherapy treatment strategy
Construct Topics covered Key findings
Intervention characteristics
Relative advantage  ►  What are the advantages of the 
proposed treatment model?
 ► Offered free of charge, outpatient
Adaptability  ►  What are other models of treatment 
that would facilitate increased access?
 ►  What are factors of the current 
treatment model that could be improved?
 ► Decentralised treatment or transportation 
support would improve the model
Complexity  ►  Perceptions of treatment feasibility and 
sustainability
 ►  What is the participant’s understanding 
of the screening and treatment cascade?
 ► Women had unanswered questions after 
treatment regarding follow-up, need for 
medication or potential impact on fertility
Outer setting
Patient needs and resources  ►  What can the health facilities do to 
facilitate patient treatment acquisition?
  
 ► Provider respect was high
Inner setting
Culture  ►  What is the level and impact of male 
support?
 ►  How could community leader 
involvement facilitate treatment?
 ► Male financial and moral support were 
important to treatment acquisition
 ► Many were concerned about post-treatment 
abstinence or re-infection
 ► Ambivalence about community leader 
involvement
Access to knowledge and information  ►  How can outreach and education 
strategies be improved?
 ►  How does peer education and support 
impact treatment acquisition?
 ► Peer education noted in both educating 
about screening and encouraging treatment
Characteristics of individuals
Knowledge and beliefs about the 
intervention
 ►  Did women understand the meaning of 
a positive HPV result?
 ►  Did women understand the process 
and availability of treatment?
 ►  Do women understand the importance 
of treatment for their health?
 ► Role of HPV in development of cancer was 
well understood, however some women 
equated an HPV-positive result with cancer
 ► Women knew that early treatment would be 
simpler than treatment for advanced disease
Self-efficacy  ►  Do women prioritise accessing 
treatment for their health?
 ►  How do health beliefs and self-efficacy 
impact women’s ability to overcome 
barriers to treatment?
 ► Women felt knowing HPV status allowed 
them to move on a health action (treatment)
 ► Treatment had an empowering influence
 ► Post-treatment, women felt that they could/
should be role models
Individual stage of change  ►  What role do peer networks or social 
support play in treatment access?
 ►  What role do individual health beliefs 
play in reactions or decisions about 
treatment for a positive HPV test?
 ► Women felt relief at knowing HPV status
 ► Fear surrounding HPV result and association 
with cancer led to some inaction
CFIR, Consolidated Framework for Implementation Research.
to discuss and make final revisions to the codebook. All 
interviews were coded twice by two separate members of 
the research team. Coding reports were then reviewed 
collaboratively to identify important themes and finalise 
mapping onto the modified CFIR framework.
Patient and public involvement
The research question and measures were informed by 
preliminary work done in partnership with the Ministry 
of Health to evaluate barriers and facilitators of cervical 
cancer screening and treatment. Prior to study implemen-
tation, we also carried out focus group discussions with 
women living in Migori to plan and implement phase I of 
the study (manuscript submitted). For this study, patients 
were not involved in identification or recruitment of 
participants, as all women undergoing treatment were 
asked by a research assistant to participate in an interview 
after their treatment had been completed. Results have 
already been disseminated to the participants through 
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two key stakeholder meetings. In addition, selected partic-
ipants were invited to participate in a working group to 
amend the treatment implementation strategy for phase 
II.
All participants gave their written informed consent to 
participate in the study prior to data collection. For low-lit-
eracy participants, consent was affirmed with thumbprint.
results
Between February and December 2016, 5898 women 
underwent cervical cancer screening in both CHC and 
health facilities and 1043 (17.4%) tested positive for HPV. 
Out of these women, 399 (38.3%) women presented for 
treatment at Migori County Hospital and 372 (35.6%) 
underwent cryotherapy. Three women were referred for 
LEEP and one for invasive cancer management. Among 
the 372 treated HPV-positive women, 273 women (73.4%) 
completed an IDI after their treatment. The average age 
for participants was 37.3 years, for 216 (79.1%) primary 
school was the highest education completed, and 206 
(75.4%) were married or had a current partner. There 
was no difference in the clinical or demographic charac-
teristics in the participants from the original study arm, or 
between those who agreed to an interview and those who 
declined. Women travelled a mean of 37 kilometres to get 
to Migori for treatment, and almost all used a paid form 
of transportation (bus, taxi or motorbike).
Knowledge and perceptions of hPV positivity and treatment 
value
Many women expressed confidence in their level of 
knowledge about the relationship between HPV and 
cervical cancer, and the role of treatment in protecting 
their health. Specifically, many understood that the 
recommended treatment was simpler and more effective 
than it would be if HPV developed into cervical cancer.
I learnt that, having HPV doesn’t mean you have the 
disease, it is just a sign that it may develop in to a dis-
ease and when you have the virus and it is detected 
early enough it can be treated. (Age 41 years)
Although many women were able to make fact-based 
statements about HPV, and professed confidence in their 
knowledge, some expressed fear, anxiety and mispercep-
tions about their positive HPV results and the association 
with cancer. This was reflected in women’s feelings around 
the time they received their results and their concern that 
the treatment would not ‘cure’ their cancer.
I felt pain at heart, since I do hear that those with can-
cer do not survive, even now I still have no assurance 
of good health. (Age 43 years)
Though some women reported worry or anxiety about 
their test result, many felt relief that they were now aware 
of their HPV status and could get treatment.
What came into my mind after I was confirmed HPV 
positive was just on how I can access treatment my 
focus now is how I can be on treatment and that is my 
key challenge as at now. (Age 47 years)
treatment experience
Women were almost uniformly positive about provider 
respect, privacy, adequate explanation of the procedure 
and recovery, and ability to ask and have their questions 
answered. Most women also reported minimal pain or 
cramping, with no reported complications with the proce-
dure. Overall, women expressed relief that the procedure 
was not as difficult as they had feared, with responses 
similar to the comment below.
When I came from home, people were saying that 
this treatment is painful but I have not felt any pain. I 
have found it to be good and the pain that people are 
talking about is not there. (Age 36 years)
When asked how to improve the treatment experience, 
women had limited suggestions, or focused on access 
issues. This may not reflect satisfaction with the treatment 
model as much as a feeling that it was the role of ‘health-
care providers’ or ‘doctors’ to ‘improve the experience’. 
‘It is you as healthcare providers to find on ways of making it 
more comfortable.’ (Age 33 years)
unanswered questions
Despite reporting adequate explanation and overall 
treatment satisfaction, a number of unanswered ques-
tions or misperceptions regarding cervical cancer or 
follow-up arose throughout the interviews. When asked 
whether women had unanswered questions at the end 
of the screening/notification and treatment process, 
they revealed underlying fears about extent of disease/
outcomes of treatment (future fertility, death from 
cancer, etc). Many women were under the impression 
that they would be given drugs to treat HPV, like treat-
ment for malaria or HIV management. ‘I have learnt that 
in case I will be given drugs then I will have to take them to 
help prevent the virus from advancing into cervical cancer’ (Age 
38 years). Women who mentioned drugs recounted that 
they were told they would be given drugs, although this 
was not an intended part of the health messaging during 
screening or treatment.
Some women believed that if they were infected with 
HPV, they would not be able to give birth, or they should 
not get pregnant because the fetus would be infected with 
HPV. Related to the fear of infertility, women reported 
believing that family planning methods caused their posi-
tive HPV result or would cause cervical cancer. ‘I thought 
that I had cervical cancer because since I went for family plan-
ning (Intrauterine Device). I have not been feeling okay in the 
uterus.’ (Age 42 years)
Identifying specific barriers and facilitators to treatment 
access
When women were asked whether they encountered any 
barriers or difficulty accessing treatment, most answered 
no. However, when prompted, many confirmed that they 
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had to miss work, struggled to find childcare or transpor-
tation funds, or travelled a long distance. Some women 
expressed the belief that if a woman is sick or valued her 
health, there were no barriers that could stop her from 
accessing treatment in statements like the following: ‘It 
can only be far for someone who is not sick but if you are sick, you 
cannot say that it is far. I’m here to save my life’ (Age 46 years).
Lack of access to means of transportation and/or funds 
to hire transport were the main barriers that resulted in 
delays in treatment. Women also worried about future 
transport costs if the disease progressed, explicitly stating 
that they anticipated missing future appointments.
I do not know what to tell you. If you have money you 
can access everywhere, but if you do not you cannot 
make it on foot. The poor will die of even diseases 
that can be treated unlike the rich. (Age 38 years)
When asked about how to make treatment access easier, 
many women mentioned that telling their own story of 
treatment to women who tested positive for HPV would 
be helpful, suggesting that peer education and social 
support may play a large role in the decision to get treated. 
Women wanted to publicise that treatment was free, easy, 
quick and important for women’s long-term health. 
Examples of these sentiments include the following:
When the (positive) results came I was surprised. I 
then took time and went to my friends who also were 
HPV positive and shared with them, we encouraged 
each other and set dates for coming for treatment. 
(Age 45 years)
I would tell her it is important for her to know her 
HPV status because she would be able to know if 
she is at a high risk of developing cervical cancer…
Treatment is good. It is free and very easy. There is 
no pain, so it is good. That is how I would encourage 
her. (Age 51 years)
Women suggested two changes in the treatment model 
that could facilitate treatment for women in the commu-
nity: (1) A decentralised treatment model that provides 
treatment in more rural health facilities, closer to homes, 
or a mobile treatment unit that moves periodically 
through communities. (2) Transportation provisions or 
reimbursements, echoing the main barrier to treatment 
access.
Finally, a substantial number of women felt that greater 
awareness of or access to screening would increase uptake 
of treatment. Women suggested repeating screening 
in the communities for those who had missed earlier 
campaigns and increasing involvement of lay health 
workers, or community health volunteers, in outreach 
and education around screening.
support from peer networks and community leaders
Women wanted to share their diagnosis with others in 
their community, both to be able to obtain psycholog-
ical and financial support for treatment and to set an 
example. Most reported that privacy around their HPV 
status was not important to them.
I am comfortable with any other person knowing my 
status because, he or she might be able to support me 
if am sick or I might be able to encourage and sup-
port a person who is sick but is too scared to receive 
treatment.
A small minority of women who did not want to share 
their diagnosis with others, apart from their spouse or 
co-wives, gave reasons including a general desire for 
privacy about their own health, without specific mention 
of HPV or cervical cancer related stigma.
The reason why I did not want anyone else to know 
is because some people tend to exaggerate things, if 
one hears you have this disease, they may start telling 
you how you have a very bad disease and that you will 
die soon.
Women held contradictory opinions regarding the role 
of community leaders in facilitating treatment. Women 
who were in favour stated that leaders could ‘mobilise 
women to seek treatment’ (Age 33 years), while those opposed 
feared a loss of privacy, stating that ‘community leaders would 
spread rumours to the community members’ (Age 37 years).
Male partner involvement
Male partner involvement was described as it related to 
treatment access, post-treatment care and fears of re-in-
fection from their partners. Almost all women interviewed 
said the decision to seek treatment was theirs alone. 
However, they did feel like male support or opposition 
played a role in access of treatment services. Interestingly, 
most women stated that while men in general would likely 
not be supportive of their wives obtaining treatment, 
their own spouse had been. Reasons for other husbands’ 
perceived lack of support were related to a lack of under-
standing or belief that HPV is a real threat, and low prior-
itisation of their wives’ health. Male support was generally 
described as financial support for transportation, with a 
minority naming encouragement or moral support for 
treatment. Women’s comments indicate either a percep-
tion about lack of male support for other women in the 
community, while descriptions of their own experience 
suggest that male support was a key factor in their ability 
to obtain treatment (as all the women in this group had 
successfully obtained treatment).
My husband support(ed) screening so that should I 
be confirmed positive, I start the treatment in time 
before it worsens…he provided me with fare and 
asked me to leave early so I can get to the hospital in 
time. (Age 42 years)
Some do not understand cervical cancer and some 
just care less about their wives and cervical cancer 
hence not becoming supportive. Other men are sup-
portive when they value the lives of their female part-
ners. (Age 33 years)
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Standard counselling after cryotherapy includes absti-
nence for a month, and use of a condom after resump-
tion of sexual activity for 6 months to prevent spread of 
HPV or reinfection. A few women expressed concern 
about cultural and social beliefs regarding sexual activity 
that would prevent their husbands from supporting 
them through the recovery period, or use of a condom 
afterwards. Some women even requested that a health 
provider speak with their husband.
I had a concern with the issue of not having sexual 
contact with my husband for a month. We built a new 
house, which we are supposed to enter into in the 
course of this week. As Luos, we have our customs 
that we must uphold, what will I do? (Age 35 years)
Concerns about the ability to be abstinent following 
treatment were echoed in some women’s thoughts about 
the futility of treatment in situations where they perceived 
little control over possible reinfection. Concerns were 
raised about safe relations with their husband, inability 
to negotiate condoms and concerns about (re-)infection 
among co-wives.
It is said that men are the one who infects us, and us 
still being a young couple we are bound to have sexu-
al relations, what can be done so to men so that they 
do not spread the disease? (Age 39 years)
Supposing I have a co-wife, how will I know that she 
has also been treated so that we can all be free and 
not use condoms? (Age 34 years)
treatment and empowerment
Although this group of women who were able to overcome 
barriers and access treatment for their HPV likely had 
higher baseline levels of empowerment than women who 
did not get treatment, many women expressed a sense of 
personal empowerment from the process of either under-
going treatment or from gaining an understanding of the 
impact of HPV on their health. This may have been as a 
key factor in overcoming barriers to treatment.
I have come to seek treatment for a better future; I 
want a future so that I can continue taking care of 
[my children] (Age 35 years)
Finally, almost all women said they would recom-
mend treatment to other women who they knew tested 
HPV-positive, stating that the treatment was easier than 
they thought, free, quick and almost painless. Impor-
tantly, many felt that they had an important role to play 
as peer educators or advocates to convince other women 
who tested HPV-positive to get treatment. Often, women 
expressed that their treatment experience changed their 
minds about privacy and the importance of sharing their 
experience.
I never felt like letting anyone know about my treat-
ment, now that I have, I can easily encourage my 
neighbour to seek for treatment in case she’s positive. 
(Age 36 years)
I would tell her my experience about the treatment. 
How easy and how painless it is. How the doctors are 
prepared and how they talk nicely to us. I would tell 
her she has nothing to fear and she should gather 
courage and come. (Age 41 years)
dIsCussIon
Appropriate follow-up for HPV-positive women is a critical 
component in cervical cancer prevention and control; 
the success of the programme in LMICs is often limited 
by attrition between screening and treatment. This study 
used the CFIR framework to explore the contextual 
factors surrounding women’s uptake of treatment after 
a positive HPV test in rural Kenya. We found that women 
were generally satisfied and even empowered by their 
treatment experience. The results also showed that the 
belief that the treatment they were seeking would have 
an important and positive impact on their health enabled 
women to overcome the barriers of fear, lack of transporta-
tion funds and distance to the treatment centre. Women’s 
responses were surprisingly consistent throughout the 
interviews, with some level of disagreement emerging 
around the importance of male involvement in their own 
ability to seek treatment compared with their perception 
of how it impacted other women.
These findings add substantially to a body of work that 
has primarily focused on structural, financial, and poli-
cy-related barriers and facilitators to the implementation 
of a cervical cancer screening and treatment programme 
by exploring the patient experience from receiving 
results to navigating treatment access.17 18 The participant 
perspectives provide important insight into ways the treat-
ment model can be improved. To our knowledge, this is 
the only study to assess patient-level factors impacting 
cryotherapy treatment in a low-resource setting using the 
CFIR framework. The use of a standardised framework 
is important to developing a sustainable and effective 
enhanced linkage to treatment strategy with the potential 
for replication in other settings.
The fact that empowerment associated with treatment 
emerged so strongly was encouraging and indicated a 
facilitating culture. However, substantial logistical and 
financial barriers remain in place for women in this 
model, despite free screening and treatment. Women 
travelled an average distance of over 30 km and almost 
all women required some form of hired transportation. 
While the majority of women did not recall income 
loss, or reported a loss of less than 1000 Kenya Shillings 
(US$10), the cost of transportation represented a signifi-
cant burden, even among this group of women who were 
not lost to follow-up. Partner support was significant, and 
most often appeared in the form of payment for trans-
portation. While almost all women stated that the deci-
sion to seek treatment was their own, their reliance on 
partners for financial support was crucial and may have 
important implications for future cervical cancer preven-
tion and treatment initiatives. The role of partner support 
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needs to be explored among women who were not able 
to obtain treatment. The frequency at which the costs of 
transportation to a distant treatment site and the reliance 
on partners were reported indicates a need to explore the 
decentralisation of treatment with or without a mobile 
treatment unit, the use of transportation vouchers or 
assistance of some type that emphasised transportation.
The use of peer educators to help encourage and facil-
itate treatment access may also be a strategy to overcome 
the logistical hurdles using an empowerment frame-
work. While other studies have not shown educational 
interventions to be as effective as other implementation 
strategies for cervical cancer prevention,19 peer-led coun-
selling has increased perceptions of screening benefits 
and engagement in screening activities.20 21 Peer-to-peer 
education has played a large role in the success of the 
HIV programme in this region, so participants were likely 
to have experience and comfort with this. Importantly, 
women saw themselves as potential peer educators, using 
their positive experiences with treatment to convince 
other women to get treated. In this way, the self-efficacy 
they displayed in obtaining treatment would be trans-
formed into a sense of personal empowerment through 
a reflection of their own success and influence on others.
These qualitative data clearly elucidated points of 
clarification for the educational counselling provided 
throughout the outreach, screening and treatment activ-
ities. Although the current education modules stress that 
HPV is not cancer, some women continued to believe 
that a positive HPV result was synonymous with having 
cancer, which then caused cancer-related fear, sometimes 
resulting in inaction. Educational content and the mecha-
nisms by which women are notified of their results should 
be rigorously tested to ensure clarity, as fear of cancer 
or more invasive procedures may prevent women from 
seeking appropriate treatment. In addition, these data 
highlight a need to address the misconceptions about 
family planning, infertility and the need for medication 
as part of treatment both during outreach and at the time 
of screening and treatment. The persistent expectation 
that treatment would involve long-term medications may 
reflect an interpretation of medication as synonymous 
with treatment, as is the case with the more common 
diseases in the area: HIV, Tuberculosis and malaria. Based 
on these findings we updated the educational material 
to include more precise descriptions of the cryotherapy 
procedure and clarify that treatment does not require 
medication.
While these data highlighted crucial information that 
allows us to further understand how and why women are 
able to access treatment when free treatment is offered, 
there are limitations inherent to the study design. The 
current study is missing the voices and experience of 
women who were unable to access treatment, who were 
the majority of women screened; this may contribute 
to the relative homogeneity of observed themes. For 
example, in this population of women who had success-
fully accessed treatment, almost all were in a relationship 
or married, which was possibly a key factor in their success 
with navigating treatment. While the qualitative data 
suggest partner financial support was key in reaching 
treatment sites, we must identify and work with women 
who were lost to follow-up to fully begin to understand 
and address insurmountable barriers. In addition, as 
these interviews were done by the study team in proximity 
to treatment sites, there may have been some social desir-
ability bias in responses related to treatment experience 
and provider respect.
ConClusIons
These data provide valuable insight on the implemen-
tation of a community-based cervical cancer screening 
programme through the perspectives of HPV-positive 
women who were able to access free treatment through 
referral to a county government hospital. While many 
women reported feelings of self-efficacy and empower-
ment, and were pleased with their experience deciding 
and accessing treatment, they represent the minority of 
patients. Despite multiple efforts to counsel women about 
the importance and availability of treatment, over half of 
the women who tested HPV-positive in the parent study 
did not access treatment. We have identified specific 
barriers and potential facilitators to treatment access that 
will inform new implementation strategies and ways to 
intensify efforts to reach the wider population of women 
who were lost to follow-up and work with healthcare teams 
to develop a linkage to treatment strategy that ensures 
greater follow-up with appropriate care.
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